vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and FGI Industries Ltd. (FGI). Click either name above to swap in a different company.
FGI Industries Ltd. is the larger business by last-quarter revenue ($30.5M vs $21.9M, roughly 1.4× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -8.6%, a 15.8% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -14.4%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -0.5%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
FGI Industries Ltd is a global designer, manufacturer and distributor of kitchen and bath products, home organization solutions, and home improvement goods. It serves major retail chains, home specialty stores and e-commerce platforms across North America, Europe and the Asia-Pacific region.
CUE vs FGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $30.5M |
| Net Profit | $1.6M | $-2.6M |
| Gross Margin | — | 26.7% |
| Operating Margin | 9.0% | -2.2% |
| Net Margin | 7.2% | -8.6% |
| Revenue YoY | 1292.3% | -14.4% |
| Net Profit YoY | 116.7% | -553.1% |
| EPS (diluted) | $0.05 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $30.5M | ||
| Q3 25 | $2.1M | $35.8M | ||
| Q2 25 | $3.0M | $31.0M | ||
| Q1 25 | $421.0K | $33.2M | ||
| Q4 24 | $1.6M | $35.6M | ||
| Q3 24 | $3.3M | $36.1M | ||
| Q2 24 | $2.7M | $29.4M | ||
| Q1 24 | $1.7M | $30.8M |
| Q4 25 | $1.6M | $-2.6M | ||
| Q3 25 | $-7.4M | $-1.7M | ||
| Q2 25 | $-8.5M | $-1.2M | ||
| Q1 25 | $-12.3M | $-629.1K | ||
| Q4 24 | — | $-402.3K | ||
| Q3 24 | $-8.7M | $-550.1K | ||
| Q2 24 | $-10.2M | $163.6K | ||
| Q1 24 | $-12.3M | $-412.2K |
| Q4 25 | — | 26.7% | ||
| Q3 25 | — | 26.5% | ||
| Q2 25 | — | 28.1% | ||
| Q1 25 | — | 26.8% | ||
| Q4 24 | — | 24.6% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 30.5% | ||
| Q1 24 | — | 27.4% |
| Q4 25 | 9.0% | -2.2% | ||
| Q3 25 | -353.4% | 1.0% | ||
| Q2 25 | -292.3% | -2.7% | ||
| Q1 25 | -2921.4% | -3.9% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | -264.2% | -0.2% | ||
| Q2 24 | -390.6% | -1.5% | ||
| Q1 24 | -737.8% | -1.0% |
| Q4 25 | 7.2% | -8.6% | ||
| Q3 25 | -346.6% | -4.6% | ||
| Q2 25 | -287.1% | -4.0% | ||
| Q1 25 | -2911.4% | -1.9% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | -259.6% | -1.5% | ||
| Q2 24 | -382.7% | 0.6% | ||
| Q1 24 | -719.1% | -1.3% |
| Q4 25 | $0.05 | $-1.63 | ||
| Q3 25 | $-0.07 | $-0.86 | ||
| Q2 25 | $-0.09 | $-0.64 | ||
| Q1 25 | $-0.17 | $-0.07 | ||
| Q4 24 | — | $-0.38 | ||
| Q3 24 | $-0.17 | $-0.29 | ||
| Q2 24 | $-0.20 | $0.08 | ||
| Q1 24 | $-0.25 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $1.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $17.3M |
| Total Assets | $42.2M | $69.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $1.9M | ||
| Q3 25 | $11.7M | $1.9M | ||
| Q2 25 | $27.5M | $2.5M | ||
| Q1 25 | $13.1M | $1.2M | ||
| Q4 24 | $22.5M | $4.6M | ||
| Q3 24 | $32.4M | $3.0M | ||
| Q2 24 | $30.0M | $1.3M | ||
| Q1 24 | $41.0M | $3.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $17.3M | ||
| Q3 25 | $13.2M | $19.7M | ||
| Q2 25 | $18.2M | $21.3M | ||
| Q1 25 | $6.6M | $21.8M | ||
| Q4 24 | $17.5M | $22.3M | ||
| Q3 24 | $25.4M | $23.5M | ||
| Q2 24 | $21.6M | $23.8M | ||
| Q1 24 | $30.0M | $23.9M |
| Q4 25 | $42.2M | $69.5M | ||
| Q3 25 | $31.6M | $73.0M | ||
| Q2 25 | $40.7M | $71.7M | ||
| Q1 25 | $22.3M | $68.5M | ||
| Q4 24 | $32.2M | $75.5M | ||
| Q3 24 | $44.8M | $74.7M | ||
| Q2 24 | $42.3M | $69.9M | ||
| Q1 24 | $54.0M | $68.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.3M |
| FCF MarginFCF / Revenue | — | 7.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-212.5K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $2.3M | ||
| Q3 25 | $-9.0M | $-1.9M | ||
| Q2 25 | $-3.4M | $7.6M | ||
| Q1 25 | $-8.2M | $-7.4M | ||
| Q4 24 | $-36.3M | $617.4K | ||
| Q3 24 | $-7.5M | $-915.0K | ||
| Q2 24 | $-10.0M | $862.1K | ||
| Q1 24 | $-9.8M | $-8.0M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $-3.4M | $7.4M | ||
| Q1 25 | $-8.3M | $-7.7M | ||
| Q4 24 | $-36.4M | $-214.1K | ||
| Q3 24 | $-7.5M | $-1.1M | ||
| Q2 24 | $-10.0M | $281.5K | ||
| Q1 24 | $-9.8M | $-8.6M |
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | -5.9% | ||
| Q2 25 | -116.5% | 23.8% | ||
| Q1 25 | -1976.7% | -23.3% | ||
| Q4 24 | -2309.3% | -0.6% | ||
| Q3 24 | -225.7% | -3.0% | ||
| Q2 24 | -376.2% | 1.0% | ||
| Q1 24 | -573.0% | -28.0% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.9% | 0.7% | ||
| Q1 25 | 35.6% | 1.1% | ||
| Q4 24 | 4.2% | 2.3% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.4% | 2.0% | ||
| Q1 24 | 3.2% | 2.0% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.27× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
FGI
| Sanitaryware | $19.1M | 63% |
| Shower System | $5.8M | 19% |
| Kitchen And Bath Other | $3.3M | 11% |
| Bath Furniture Products | $2.3M | 7% |
